WO1999009142A1 - Encapsulation of living tissue cells in a microsphere - Google Patents

Encapsulation of living tissue cells in a microsphere Download PDF

Info

Publication number
WO1999009142A1
WO1999009142A1 PCT/US1998/016944 US9816944W WO9909142A1 WO 1999009142 A1 WO1999009142 A1 WO 1999009142A1 US 9816944 W US9816944 W US 9816944W WO 9909142 A1 WO9909142 A1 WO 9909142A1
Authority
WO
WIPO (PCT)
Prior art keywords
solution
living tissue
tissue cells
mixture
cells
Prior art date
Application number
PCT/US1998/016944
Other languages
French (fr)
Inventor
Edward J. A. Pope
Original Assignee
Solgene Therapeutics, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solgene Therapeutics, Llc filed Critical Solgene Therapeutics, Llc
Priority to JP2000509809A priority Critical patent/JP2001514880A/en
Priority to AU87843/98A priority patent/AU8784398A/en
Priority to EP98939412A priority patent/EP1007634A1/en
Publication of WO1999009142A1 publication Critical patent/WO1999009142A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • C—CHEMISTRY; METALLURGY
    • C03—GLASS; MINERAL OR SLAG WOOL
    • C03C—CHEMICAL COMPOSITION OF GLASSES, GLAZES OR VITREOUS ENAMELS; SURFACE TREATMENT OF GLASS; SURFACE TREATMENT OF FIBRES OR FILAMENTS MADE FROM GLASS, MINERALS OR SLAGS; JOINING GLASS TO GLASS OR OTHER MATERIALS
    • C03C4/00—Compositions for glass with special properties
    • C03C4/0007—Compositions for glass with special properties for biologically-compatible glass
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K11/00—Luminescent, e.g. electroluminescent, chemiluminescent materials
    • C09K11/02—Use of particular materials as binders, particle coatings or suspension media therefor
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K11/00—Luminescent, e.g. electroluminescent, chemiluminescent materials
    • C09K11/04—Luminescent, e.g. electroluminescent, chemiluminescent materials containing natural or artificial radioactive elements or unspecified radioactive elements
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K11/00—Luminescent, e.g. electroluminescent, chemiluminescent materials
    • C09K11/06—Luminescent, e.g. electroluminescent, chemiluminescent materials containing organic luminescent materials
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K11/00—Luminescent, e.g. electroluminescent, chemiluminescent materials
    • C09K11/08—Luminescent, e.g. electroluminescent, chemiluminescent materials containing inorganic luminescent materials
    • C09K11/59—Luminescent, e.g. electroluminescent, chemiluminescent materials containing inorganic luminescent materials containing silicon
    • C09K11/592—Chalcogenides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/04—Enzymes or microbial cells immobilised on or in an organic carrier entrapped within the carrier, e.g. gel or hollow fibres
    • G—PHYSICS
    • G02—OPTICS
    • G02F—OPTICAL DEVICES OR ARRANGEMENTS FOR THE CONTROL OF LIGHT BY MODIFICATION OF THE OPTICAL PROPERTIES OF THE MEDIA OF THE ELEMENTS INVOLVED THEREIN; NON-LINEAR OPTICS; FREQUENCY-CHANGING OF LIGHT; OPTICAL LOGIC ELEMENTS; OPTICAL ANALOGUE/DIGITAL CONVERTERS
    • G02F1/00—Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulating; Non-linear optics
    • G02F1/01—Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulating; Non-linear optics for the control of the intensity, phase, polarisation or colour 
    • G02F1/13—Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulating; Non-linear optics for the control of the intensity, phase, polarisation or colour  based on liquid crystals, e.g. single liquid crystal display cells
    • G02F1/133—Constructional arrangements; Operation of liquid crystal cells; Circuit arrangements
    • G02F1/1333—Constructional arrangements; Manufacturing methods
    • G02F1/1335—Structural association of cells with optical devices, e.g. polarisers or reflectors
    • G02F1/1336—Illuminating devices
    • G02F1/133617—Illumination with ultraviolet light; Luminescent elements or materials associated to the cell
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01J—ELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS
    • H01J29/00—Details of cathode-ray tubes or of electron-beam tubes of the types covered by group H01J31/00
    • H01J29/02—Electrodes; Screens; Mounting, supporting, spacing or insulating thereof
    • H01J29/10—Screens on or from which an image or pattern is formed, picked up, converted or stored
    • H01J29/18—Luminescent screens
    • H01J29/30—Luminescent screens with luminescent material discontinuously arranged, e.g. in dots, in lines
    • H01J29/32—Luminescent screens with luminescent material discontinuously arranged, e.g. in dots, in lines with adjacent dots or lines of different luminescent material, e.g. for colour television
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/126—Immunoprotecting barriers, e.g. jackets, diffusion chambers
    • G—PHYSICS
    • G02—OPTICS
    • G02F—OPTICAL DEVICES OR ARRANGEMENTS FOR THE CONTROL OF LIGHT BY MODIFICATION OF THE OPTICAL PROPERTIES OF THE MEDIA OF THE ELEMENTS INVOLVED THEREIN; NON-LINEAR OPTICS; FREQUENCY-CHANGING OF LIGHT; OPTICAL LOGIC ELEMENTS; OPTICAL ANALOGUE/DIGITAL CONVERTERS
    • G02F1/00—Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulating; Non-linear optics
    • G02F1/01—Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulating; Non-linear optics for the control of the intensity, phase, polarisation or colour 
    • G02F1/0102—Constructional details, not otherwise provided for in this subclass

Definitions

  • the field of the present invention is microsphere encapsulation of living tissue.
  • a process for synthesizing amorphous silica microspheres which includes the steps of placing into a container an organosilicon precursor and with a highly acidic solution and rinsing with a solvate to remove excess of the organosilicon precursor from the amorphous silica microspheres.
  • the organosilicon precursor and the highly acidic solution are immiscible.
  • the process for synthesizing amorphous silica microspheres also includes the steps adding a dopant from a group consisting of rhodamine-6G, rhodamine-B, europium 3+ , fluorescein, coumarin-120, coumarin-314T, thionine, uranium and uranium-sensitized europium, stirring the organosilicon precursor and the highly acidic solution to form droplets of the organosilicon precursor in the highly acidic solution whereby water in the highly acidic solution hydrolizes the droplets of the organosilicon precursor to form amorphous silica microspheres and rinsing with a solvent to remove excess of the organosilicon precursor therefrom.
  • the results provide fluorescence behavior.
  • tissue cells and microbial cells such as yeast cells are encapsulated in an inorganic gel prepared from an organosilicon.
  • Encapsulation of tissue cells is performed by mixing an organosilicon precursor with a highly acidic aqueous solution to hydrolyze the organosilicon precursor and provide a gel forming solution, cooling the gel forming solution, forming a mixture of living tissue cells and Hank's balanced salt solution, adding a base solution to the gel forming solution, immediately thereafter adding the mixture containing tissue cells to the gel forming solution, and pouring the resultant mixture into a container where an inorganic gel forms encapsulating the tissue cells.
  • the organosilicon precursor may be tetraethoxysilane, tetrabutoxysilane, tetramethoxysilane or tetrapropoxysilane .
  • Microbial cells are encapsulated by a similar procedure where a gel forming solution is prepared by adding a base to a solution resulting from hydrolyzing an organosilicon with a highly acidic aqueous solution, a microbial cell dispersion is mixed with the gel forming solution and the resultant mixture is poured into a container to form an inorganic gel encapsulating the microbial cells.
  • the present invention is generally directed to a process for encapsulating a living tissue cell in a microsphere .
  • the process for encapsulating living tissue cells in a plurality of microspheres includes the steps of mixing an organometallic precursor and a hydrolyzing solution to form a gel forming solution, mixing living tissue cells and a salt solution to form a solution containing living tissue cells and mixing the solution containing living tissue cells with the gel forming solution to form a mixture of a specific density.
  • the process also includes the steps of mixing the mixture into a container containing an oil and stirring the mixture to form a plurality of microspheres each of which encapsulates some of the living tissue cells.
  • the oil is immiscible with the mixture and has a lower specific density than the specific density of the mixture.
  • the process also includes the steps of forming droplets of the mixture and putting the droplets into a column of an oil.
  • the oil is immiscible with the mixture and has a lower specific density than the specific density of the mixture at the top thereof to form a plurality of microspheres each of which encapsulates some of the living tissue cells.
  • the organosilicon precursor is selected from a group consisting of tetraethoxysilane, tetrabutoxysilane, tetramethoxysilane and tetrapropoxysilane.
  • the living tissue cells are from an animal.
  • the living tissue cells are from a plant. In a sixth separate aspect of the present invention, the living tissue cells are from fungi.
  • the living tissue cells are from bacteria.
  • Ceramic material can be used to encapsulate live tissue cells that can secrete therapeutic compounds and are implanted in a host (patient) to mimic a natural organ's delivery of therapeutic compounds.
  • the live tissue may be genetically engineered to enhance or accomplish the desired result .
  • the ceramic material is porous enough to allow passage of the therapeutic molecules, but the openings are small enough to isolate the implanted cells from the host's immune system.
  • the inorganic encapsulating material is biologically inert, which reduces the risk of immune or autoimmune responses.
  • Fig. 1 is a side elevation of a stir bar and a container which contains an oil and into which the mixture of the solution containing living tissue cells with the gel forming solution to form a mixture according to the first embodiment of the present invention.
  • Fig. 2 is a side elevation of a dropper and a column of an oil into which the mixture of the solution containing living tissue cells with the gel forming solution to form a mixture according to the second embodiment of the present invention.
  • a process for synthesizing a sol-gel encapsulating living tissue cells includes the steps of placing into a first container an organometallic precursor and a hydrolyzing solution, stirring the solution until the solution becomes clear, chilling the clear solution in an ice bath, placing into a second container living tissue cells and a balanced salt solution to form a tissue solution.
  • Living tissue cells are harvested.
  • the living tissue cells are placed in a balanced salt solution to form a tissue solution.
  • the solution for human cells can be a common medical saline solution. The need is to balance sufficiently the salinity with the cells to be encapsulated to avoid rupture.
  • U.S. Patent No. 4,797,213 teaches the use of Hanks ' balanced salt solution in column 6, line 10.
  • the living tissue cells may be from a plant, an animal, bacteria, fungi or yeast.
  • the organometallic precursor may be an organosilicon precursor and the hydrolyzing solution may be a highly acidic solution having a molar concentration of acid in the range of 0.05 to 2.5.
  • the process also includes the steps of adding a base solution having a molar concentration of base in the range of 0.05 to 2.5 to the clear solution, immediately thereafter adding the tissue solution to the clear solution and the base solution, stirring the clear solution, the base solution and the tissue solution to form a gel forming solution and treating the gel forming solution to achieve the desired physical structure of the inorganic gel encapsulating the living tissue cells.
  • the base solution is added to neutralize sufficiently the solution to avoid cell damage from an extreme pH.
  • the organosilicon precursor may be selected from a group consisting of tetraethoxysilane, tetrabutoxysilane, tetramethoxysilane, tetrapropoxysilane and methyl trimethoxysilane.
  • the organometallic precursor may be selected from a group consisting of aluminum tri-n- propoxide, aluminum tri (sec) butoxide, aluminum acetoacetic ester chelate di (sec) butoxide, zirconium tri (sec)butoxide, boron butoxide, boron methoxide, titanium (iv) butoxide, titanium isopropoxide and zirconium isopropoxide .
  • the highly acidic solution is selected from a group consisting of nitric acid (HN0 3 ) and hydrochloric acid (HC1) .
  • Other highly acidic solutions may also be used including sulfuric acide (H 2 S0 4) .
  • the base solution is ammonium hydroxide. Please refer to C. J. Brinker, Journal of Non-Crystaline Solutions, Volume 48, page 48 and Volume 63, page 45.
  • Tissue cells of a plant may be harvested from a leaf by grinding the leaf into leaf- fragments. The leaf-fragments are are placed in a balanced salt solution to form a plant tissue solution.
  • Tissue cells of an animal may be harvested from the liver, the pancreas, the thyroid, the parathyroid, the pituitary gland and the renal cortex of mammals including man.
  • the sol-gel which encapsulates one of these tissue cells may be used in an artificial organ such as either an artificial liver or an artificial pancreas.
  • living animal tissue cells have been harvested from beef liver (bovine hepatocytes) .
  • the standard procedure for dispersing living animal tissue cells is to cut beef liver into small cubes. About 10 grams of the small cubes of beef liver are placed in 60 milliliters of Hanks' balanced salt solution for one half hour in order to remove the hemoglobin from the beef lever. The Hanks' balanced salt solution is removed. Forty milligrams of collagenase and sixty milligrams of dispase are dissolved in the Hanks ' balanced salt solution. Dispase and collagenase are enzymes. The Hanks ' balanced salt solution is shaken for one half hour and decented to form a tissue solution. The tissue solution is a supernatent solution which has individual living liver cells dispersed therein. The inventor has encapsulated liver cells in an organic gel.
  • U. S. Patent No. 5,270,192 teaches a hepatocyte bioreactor, a bioartificial liver, which includes a containment vessel having a perfusion inlet and a perfusion outlet, a matrix within the containment vessel so as to entrap hepatocyte aggregates within the containment vessel while allowing perfusion of the matrix.
  • U. S. Patent No. 4,391,909 teaches tissue cells such as islet of Langerhans cells or liver cells which are encapsulated within a spheroidal semipermeable membrane including a polysaccharide having acidic groups cross-linked with a polymer having a molecular weight greater than 3,000.
  • the cells within the microcapsules are viable, healthy, physiologically active and capable of ongoing metabolism.
  • the encapsulated cells are useful for implantation in a mammalian body to produce substances and effect chemical changes characteristic of the cells in vivo tissue.
  • the inventor has encapsulated islet of Langerhans cells in an organic gel .
  • the composition includes a matrix capable of delivering BMP-2A, BMP-2B or other BMP protein to the site of bone and/or cartilage damage, providing a structure for the developing bone and cartilage and optimally capable of being resorbed into the body.
  • matrices may be formed of materials presently in use for other implanted medical DNA sequences encoding the osteoinductive proteins applications.
  • the choice of matrix material is based on biocompatibility, biodegradability, mechanical properties, cosmetic appearance and interface properties.
  • the particular application of the BMP-2 compositions will define the appropriate formulation.
  • Potential matrices for the compositions may be biodegradable and chemically defined calcium sulfate, tricalciumphosphate, hydroxyapatite, polylactic acid and polyanhydrides .
  • Other potential materials are biodegradable and biologically well defined, such as bone or dermal collagen.
  • Further matrices consists of pure proteins or extracellular matrix components.
  • Other potential matrices are nonbiodegradable and chemically defined, such as sintered hydroxyapatite, bioglass, aluminates, or other ceramics .
  • Matrices may be comprised of combinations of any of the above mentioned types of material, such as polylactic acid and hydroxyapatite or collagen and tricalciumphosphate.
  • the bioceramics may be altered in composition, such as in calcium-aluminate-phosphate and processing to alter pore size, particle size, particle shape, and biodegradability.
  • the dosage regimen will be determined by the attending physician considering various factors which modify the action of the BMP-2 protein, e.g. amount of bone weight desired to be formed, the site of bone damage, the condition of the damaged bone, the size of a wound, type of damaged tissue, the patient's age, sex, and diet, the severity of any infection, time of administration and other clinical f ctors.
  • the dosage may vary with the type of matrix used in the reconstitution and the types of BMP proteins in the composition.
  • the addition of other known growth factors, such as IGF I (insulin like growth factor I) may also effect the dosage.
  • the biological substance of U. S. Patent No. 5,453,368 includes PC-12 cells which were cultured in standard RPMI .
  • the cells were taken up by pipette, placed in centrifuge tubes and spun down.
  • the cells were brought up to a volume of 2 ml, to a cell concentration of approximately 2xl0 6 to 5xl0 6 per ml.
  • the cell containing liquid was placed in sterile Hamilton syringe and placed on a Harvard apparatus injector pump.
  • the pump was connected via 18 gauge polytetra-fluoroethylene tubing to a 24 gauge stainless steel tube, which served as an apparatus for dropping the liquid.
  • Microcapsules containing bovine adrenal chromaffin cells in a 1.5% sodium alginate solution (W/V) were prepared.
  • the PBS collection bath container contained 1.5% (W/V) calcium chloride. After six weeks in culture, the microcapsules contained viable cells.
  • Red apple ground cover leaf cells (individual chlorophyl-containing cells extracted from supernatent of ground leaves) .
  • Photobacterium phosphoreum bioluminescent marine bacteria
  • Geospirillum arsenophiluf MIT-13
  • Murine islets of Langerhans Porcine islets of Langerhans, Bovine hepatocytes.
  • Porcine hepatocytes Human white blood cells, Human red blood cells,
  • Rat PC-12 cells (from rat pheochromocytoma) , Lac-z transfected murine mesenchymal stem cells
  • the process for encapsulating living tissue cells in a plurality of microspheres includes the steps of mixing an organometallic precursor and a hydrolyzing solution to form a gel forming solution, mixing living tissue cells and a salt solution to form a solution containing living tissue cells and mixing the solution containing living tissue cells with the gel forming solution to form a mixture of a specific density.
  • the living tissue cells are from either an animal or a plant.
  • the process also includes the steps of mixing the mixture into a container 11 containing an oil 12 and stirring with a stir bar 13 the mixture to form a plurality of microspheres 14. Each microsphere 14 encapsulates some of the living tissue cells.
  • the oil 12 is immiscible with the mixture and has a lower specific density than the specific density of the mixture.
  • the organometallic precursor may be a organosilicon precursor.
  • the organosilicon precursor may be selected from a group consisting of tetraethoxysilane, tetra-butoxysilane, tetramethoxysilane and tetrapropoxysilane . Referring to Fig. 2 a process is disclosed for encapsulating a living tissue cell in a microsphere.
  • the process for encapsulating living tissue cells in a plurality of microspheres includes the steps of mixing an organometallic precursor and a hydrolyzing solution to form a gel forming solution, mixing living tissue cells and a salt solution to form a solution containing living tissue cells and mixing the solution containing living tissue cells with the gel forming solution to form a mixture of a specific density.
  • the living tissue cells are from either an animal or a plant .
  • the process also includes the steps of forming droplets of the mixture and putting the droplets into a column 111 of an oil 112.
  • the oil 112 is immiscible with the mixture and has a lower specific density than the specific density of the mixture at the top thereof to form a plurality of microspheres.
  • the organometallic precursor may be a organosilicon precursor.
  • the organosilicon precursor may be selected from a group consisting of tetraethoxysilane, tetra-butoxysilane, tetramethoxysilane and tetra-propoxysilane .

Abstract

A process for encapsulating living tissue cells in a plurality of microspheres includes the steps of mixing an organometallic precursor and a hydrolyzing solution to form a gel forming solution, mixing living tissue cells and a salt solution to form a solution containing living tissue cells and mixing the solution containing living tissue cells resulting with the gel forming solution resulting to form a mixture of a specific density. The process for encapsulating living tissue cells in a plurality of microspheres also includes the steps of mixing the mixture into a container containing an oil and stirring the mixture to form a plurality of microspheres each of which encapsulates some of the living tissue cells. The oil is immiscible with the mixture and has a lower density than the mixture.

Description

DESCRIPTION
ENCAPSULATION OF LIVING TISSUE CELLS IN A MICROSPHERE
Field of the Invention
The field of the present invention is microsphere encapsulation of living tissue.
A process for synthesizing amorphous silica microspheres is known which includes the steps of placing into a container an organosilicon precursor and with a highly acidic solution and rinsing with a solvate to remove excess of the organosilicon precursor from the amorphous silica microspheres. The organosilicon precursor and the highly acidic solution are immiscible. The process for synthesizing amorphous silica microspheres also includes the steps adding a dopant from a group consisting of rhodamine-6G, rhodamine-B, europium 3+ , fluorescein, coumarin-120, coumarin-314T, thionine, uranium and uranium-sensitized europium, stirring the organosilicon precursor and the highly acidic solution to form droplets of the organosilicon precursor in the highly acidic solution whereby water in the highly acidic solution hydrolizes the droplets of the organosilicon precursor to form amorphous silica microspheres and rinsing with a solvent to remove excess of the organosilicon precursor therefrom. The results provide fluorescence behavior.
In another known process, living animal tissue cells and microbial cells such as yeast cells are encapsulated in an inorganic gel prepared from an organosilicon. Encapsulation of tissue cells is performed by mixing an organosilicon precursor with a highly acidic aqueous solution to hydrolyze the organosilicon precursor and provide a gel forming solution, cooling the gel forming solution, forming a mixture of living tissue cells and Hank's balanced salt solution, adding a base solution to the gel forming solution, immediately thereafter adding the mixture containing tissue cells to the gel forming solution, and pouring the resultant mixture into a container where an inorganic gel forms encapsulating the tissue cells. The organosilicon precursor may be tetraethoxysilane, tetrabutoxysilane, tetramethoxysilane or tetrapropoxysilane . Microbial cells are encapsulated by a similar procedure where a gel forming solution is prepared by adding a base to a solution resulting from hydrolyzing an organosilicon with a highly acidic aqueous solution, a microbial cell dispersion is mixed with the gel forming solution and the resultant mixture is poured into a container to form an inorganic gel encapsulating the microbial cells.
Summary Of The Invention
The present invention is generally directed to a process for encapsulating a living tissue cell in a microsphere . The process for encapsulating living tissue cells in a plurality of microspheres includes the steps of mixing an organometallic precursor and a hydrolyzing solution to form a gel forming solution, mixing living tissue cells and a salt solution to form a solution containing living tissue cells and mixing the solution containing living tissue cells with the gel forming solution to form a mixture of a specific density.
In a first separate aspect of the present invention, the process also includes the steps of mixing the mixture into a container containing an oil and stirring the mixture to form a plurality of microspheres each of which encapsulates some of the living tissue cells. The oil is immiscible with the mixture and has a lower specific density than the specific density of the mixture.
In a second separate aspect of the present invention, the process also includes the steps of forming droplets of the mixture and putting the droplets into a column of an oil. The oil is immiscible with the mixture and has a lower specific density than the specific density of the mixture at the top thereof to form a plurality of microspheres each of which encapsulates some of the living tissue cells.
In a third separate aspect of the present invention, the organosilicon precursor is selected from a group consisting of tetraethoxysilane, tetrabutoxysilane, tetramethoxysilane and tetrapropoxysilane.
In a fourth separate aspect of the present invention, the living tissue cells are from an animal.
In a fifth separate aspect of the present invention, the living tissue cells are from a plant. In a sixth separate aspect of the present invention, the living tissue cells are from fungi.
In a seventh separate aspect of the present invention, the living tissue cells are from bacteria.
The encapsulation of living tissue by this process creates a new drug delivery system enabling the implantation of live cells that secrete therapeutic compounds without the need for immunosuppression. Ceramic material can be used to encapsulate live tissue cells that can secrete therapeutic compounds and are implanted in a host (patient) to mimic a natural organ's delivery of therapeutic compounds. The live tissue may be genetically engineered to enhance or accomplish the desired result . The ceramic material is porous enough to allow passage of the therapeutic molecules, but the openings are small enough to isolate the implanted cells from the host's immune system. The inorganic encapsulating material is biologically inert, which reduces the risk of immune or autoimmune responses.
Other aspects and many of the attendant advantages will be more readily appreciated as the same becomes better understood by reference to the following detailed description. The features of the present invention which are believed to be novel are set forth with particularity in the appended claims.
Description Of The Drawings
Fig. 1 is a side elevation of a stir bar and a container which contains an oil and into which the mixture of the solution containing living tissue cells with the gel forming solution to form a mixture according to the first embodiment of the present invention.
Fig. 2 is a side elevation of a dropper and a column of an oil into which the mixture of the solution containing living tissue cells with the gel forming solution to form a mixture according to the second embodiment of the present invention.
Detailed Description Of The Preferred Embodiments A process for synthesizing a sol-gel encapsulating living tissue cells includes the steps of placing into a first container an organometallic precursor and a hydrolyzing solution, stirring the solution until the solution becomes clear, chilling the clear solution in an ice bath, placing into a second container living tissue cells and a balanced salt solution to form a tissue solution. Living tissue cells are harvested. The living tissue cells are placed in a balanced salt solution to form a tissue solution. The solution for human cells can be a common medical saline solution. The need is to balance sufficiently the salinity with the cells to be encapsulated to avoid rupture. U.S. Patent No. 4,797,213 teaches the use of Hanks' balanced salt solution in column 6, line 10. The living tissue cells may be from a plant, an animal, bacteria, fungi or yeast. The organometallic precursor may be an organosilicon precursor and the hydrolyzing solution may be a highly acidic solution having a molar concentration of acid in the range of 0.05 to 2.5. The process also includes the steps of adding a base solution having a molar concentration of base in the range of 0.05 to 2.5 to the clear solution, immediately thereafter adding the tissue solution to the clear solution and the base solution, stirring the clear solution, the base solution and the tissue solution to form a gel forming solution and treating the gel forming solution to achieve the desired physical structure of the inorganic gel encapsulating the living tissue cells. The base solution is added to neutralize sufficiently the solution to avoid cell damage from an extreme pH. The organosilicon precursor may be selected from a group consisting of tetraethoxysilane, tetrabutoxysilane, tetramethoxysilane, tetrapropoxysilane and methyl trimethoxysilane. The organometallic precursor may be selected from a group consisting of aluminum tri-n- propoxide, aluminum tri (sec) butoxide, aluminum acetoacetic ester chelate di (sec) butoxide, zirconium tri (sec)butoxide, boron butoxide, boron methoxide, titanium (iv) butoxide, titanium isopropoxide and zirconium isopropoxide . The highly acidic solution is selected from a group consisting of nitric acid (HN03) and hydrochloric acid (HC1) . Other highly acidic solutions may also be used including sulfuric acide (H2S04) . In the preferred embodiment the base solution is ammonium hydroxide. Please refer to C. J. Brinker, Journal of Non-Crystaline Solutions, Volume 48, page 48 and Volume 63, page 45.
Chapter 13 on page 141 of the book entitled Animal Cell Culture, edited by Jeffrey W. Pollard and John M. Walker and published by Humana Press which is located in Clifton, New Jersey, describes Hanks' Balanced Salt Solution.
The manual entitled Plant Tissue Culture Manual : Fundamentals and Applications, edited by K. Lindsey and published by Humana Press. Tissue cells of a plant may be harvested from a leaf by grinding the leaf into leaf- fragments. The leaf-fragments are are placed in a balanced salt solution to form a plant tissue solution. Chapter 13 on page 141 of the book entitled 7Animal Cell Culture, edited by Jeffrey W. Pollard and John M. Walker and published by Humana Press which is located in Clifton, New Jersey, also describes the harvesting of tissue cells of an animal. Tissue cells of an animal may be harvested from the liver, the pancreas, the thyroid, the parathyroid, the pituitary gland and the renal cortex of mammals including man. The sol-gel which encapsulates one of these tissue cells may be used in an artificial organ such as either an artificial liver or an artificial pancreas.
For example, living animal tissue cells have been harvested from beef liver (bovine hepatocytes) . The standard procedure for dispersing living animal tissue cells is to cut beef liver into small cubes. About 10 grams of the small cubes of beef liver are placed in 60 milliliters of Hanks' balanced salt solution for one half hour in order to remove the hemoglobin from the beef lever. The Hanks' balanced salt solution is removed. Forty milligrams of collagenase and sixty milligrams of dispase are dissolved in the Hanks ' balanced salt solution. Dispase and collagenase are enzymes. The Hanks ' balanced salt solution is shaken for one half hour and decented to form a tissue solution. The tissue solution is a supernatent solution which has individual living liver cells dispersed therein. The inventor has encapsulated liver cells in an organic gel.
U. S. Patent No. 5,270,192 teaches a hepatocyte bioreactor, a bioartificial liver, which includes a containment vessel having a perfusion inlet and a perfusion outlet, a matrix within the containment vessel so as to entrap hepatocyte aggregates within the containment vessel while allowing perfusion of the matrix.
U. S. Patent No. 4,391,909 teaches tissue cells such as islet of Langerhans cells or liver cells which are encapsulated within a spheroidal semipermeable membrane including a polysaccharide having acidic groups cross-linked with a polymer having a molecular weight greater than 3,000. The cells within the microcapsules are viable, healthy, physiologically active and capable of ongoing metabolism. The encapsulated cells are useful for implantation in a mammalian body to produce substances and effect chemical changes characteristic of the cells in vivo tissue. The inventor has encapsulated islet of Langerhans cells in an organic gel .
U. S. Patent No. 5,166,058 teaches purified BMP-2 proteins which may be used in the treatment of bone and cartilage defects and in wound healing and related tissue repair. For bone and/or cartilage formation, the composition includes a matrix capable of delivering BMP-2A, BMP-2B or other BMP protein to the site of bone and/or cartilage damage, providing a structure for the developing bone and cartilage and optimally capable of being resorbed into the body. Such matrices may be formed of materials presently in use for other implanted medical DNA sequences encoding the osteoinductive proteins applications. The choice of matrix material is based on biocompatibility, biodegradability, mechanical properties, cosmetic appearance and interface properties. The particular application of the BMP-2 compositions will define the appropriate formulation. Potential matrices for the compositions may be biodegradable and chemically defined calcium sulfate, tricalciumphosphate, hydroxyapatite, polylactic acid and polyanhydrides . Other potential materials are biodegradable and biologically well defined, such as bone or dermal collagen. Further matrices consists of pure proteins or extracellular matrix components. Other potential matrices are nonbiodegradable and chemically defined, such as sintered hydroxyapatite, bioglass, aluminates, or other ceramics . Matrices may be comprised of combinations of any of the above mentioned types of material, such as polylactic acid and hydroxyapatite or collagen and tricalciumphosphate. The bioceramics may be altered in composition, such as in calcium-aluminate-phosphate and processing to alter pore size, particle size, particle shape, and biodegradability. The dosage regimen will be determined by the attending physician considering various factors which modify the action of the BMP-2 protein, e.g. amount of bone weight desired to be formed, the site of bone damage, the condition of the damaged bone, the size of a wound, type of damaged tissue, the patient's age, sex, and diet, the severity of any infection, time of administration and other clinical f ctors. The dosage may vary with the type of matrix used in the reconstitution and the types of BMP proteins in the composition. The addition of other known growth factors, such as IGF I (insulin like growth factor I) , to the final composition, may also effect the dosage.
The biological substance of U. S. Patent No. 5,453,368 includes PC-12 cells which were cultured in standard RPMI . The cells were taken up by pipette, placed in centrifuge tubes and spun down. The cells were brought up to a volume of 2 ml, to a cell concentration of approximately 2xl06 to 5xl06 per ml. The cell containing liquid was placed in sterile Hamilton syringe and placed on a Harvard apparatus injector pump. The pump was connected via 18 gauge polytetra-fluoroethylene tubing to a 24 gauge stainless steel tube, which served as an apparatus for dropping the liquid. Microcapsules containing bovine adrenal chromaffin cells in a 1.5% sodium alginate solution (W/V) were prepared. The PBS collection bath container contained 1.5% (W/V) calcium chloride. After six weeks in culture, the microcapsules contained viable cells.
The following cells have been successfully encapsulated and remained viable in silica gels using the foregoing process . In fungi :
Saccharomyces cerevisiae, Phanerochaete chrysosporium. In plants :
Pyrocystis lunula (photosynthetic marine algae) ,
Red apple ground cover leaf cells (individual chlorophyl-containing cells extracted from supernatent of ground leaves) . In bacteria:
Photobacterium phosphoreum (bioluminescent marine bacteria) , Geospirillum arsenophiluf (MIT-13) ,
Halobacterium halobium. In animals :
Murine islets of Langerhans, Porcine islets of Langerhans, Bovine hepatocytes.
Porcine hepatocytes, Human white blood cells, Human red blood cells,
Rat PC-12 cells (from rat pheochromocytoma) , Lac-z transfected murine mesenchymal stem cells
(genetically engineed mammalian tissue cells) , Rat fibroblasts, Human fibroblasts, Human osteosarcoma cells, Chinese hamster ovarian (CHO) cells.
Referring to Fig. 1 a process is disclosed for encapsulating a living tissue cell in a microsphere . The process for encapsulating living tissue cells in a plurality of microspheres includes the steps of mixing an organometallic precursor and a hydrolyzing solution to form a gel forming solution, mixing living tissue cells and a salt solution to form a solution containing living tissue cells and mixing the solution containing living tissue cells with the gel forming solution to form a mixture of a specific density. The living tissue cells are from either an animal or a plant. The process also includes the steps of mixing the mixture into a container 11 containing an oil 12 and stirring with a stir bar 13 the mixture to form a plurality of microspheres 14. Each microsphere 14 encapsulates some of the living tissue cells. The oil 12 is immiscible with the mixture and has a lower specific density than the specific density of the mixture. The organometallic precursor may be a organosilicon precursor. The organosilicon precursor may be selected from a group consisting of tetraethoxysilane, tetra-butoxysilane, tetramethoxysilane and tetrapropoxysilane . Referring to Fig. 2 a process is disclosed for encapsulating a living tissue cell in a microsphere. The process for encapsulating living tissue cells in a plurality of microspheres includes the steps of mixing an organometallic precursor and a hydrolyzing solution to form a gel forming solution, mixing living tissue cells and a salt solution to form a solution containing living tissue cells and mixing the solution containing living tissue cells with the gel forming solution to form a mixture of a specific density. The living tissue cells are from either an animal or a plant . The process also includes the steps of forming droplets of the mixture and putting the droplets into a column 111 of an oil 112. The oil 112 is immiscible with the mixture and has a lower specific density than the specific density of the mixture at the top thereof to form a plurality of microspheres. Each microsphere 114 encapsulates some of the living tissue cells. The organometallic precursor may be a organosilicon precursor. The organosilicon precursor may be selected from a group consisting of tetraethoxysilane, tetra-butoxysilane, tetramethoxysilane and tetra-propoxysilane .
From the foregoing it can be seen that a sol-gel encapsulating an active biological materials, including tissue cells of an animal and micro-organisms, has been described. Accordingly it is intended that the foregoing disclosure shall be considered only as an illustration of the principle of the present invention.

Claims

Claims
1. A process for encapsulating living tissue cells in a plurality of microspheres comprising a. combining an organometallic precursor and a hydrolyzing solution to form a gel forming solution; b. combining living tissue cells and a salt solution to form a solution containing living tissue cells; c. combining the solution containing living tissue cells resulting from step b with the gel forming solution resulting from step a to form a mixture of a specific density; d. mixing the mixture resulting from step c into an oil which is immiscible with the mixture resulting from step c and has a lower specific density than the specific density of the mixture resulting from step c to form a plurality of microspheres encapsulating some of said living tissue cells.
2. The process of claim 1, the step of mixing including stirring the combination of the oil and the mixture resulting from step c.
3. The process of claim 1, the step of mixing including forming droplets of the mixture resulting from step c and putting the droplets into the top of a column of the oil.
4. The process of claim 1, 2 or 3, the organometallic precursor being an organosilicon precursor in the step of combining the organometallic precursor and the hydrolyzing solution.
5. The process of claim 4, the organosilicon precursor being selected from a group consisting of tetraethoxysilane, tetrabutoxysilane, tetramethoxysilane and tetrapropoxysilane.
6. The process of claim 1, 2 or 3 further comprising e. combining the gel forming solution resulting from step a with a base before the step of combining the gel forming solution with the solution containing living tissue cells resulting from step b to neutralize sufficiently the gel forming solution to avoid damage to the living tissue cells from an extreme pH.
PCT/US1998/016944 1997-08-18 1998-08-14 Encapsulation of living tissue cells in a microsphere WO1999009142A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2000509809A JP2001514880A (en) 1997-08-18 1998-08-14 Encapsulation of living tissue cells into microspheres
AU87843/98A AU8784398A (en) 1997-08-18 1998-08-14 Encapsulation of living tissue cells in a microsphere
EP98939412A EP1007634A1 (en) 1997-08-18 1998-08-14 Encapsulation of living tissue cells in a microsphere

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/912,771 US5895757A (en) 1993-06-30 1997-08-18 Encapsulation of living tissue cells in inorganic microspheres prepared from an organosilicon
US08/912,771 1997-08-18

Publications (1)

Publication Number Publication Date
WO1999009142A1 true WO1999009142A1 (en) 1999-02-25

Family

ID=25432417

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/016944 WO1999009142A1 (en) 1997-08-18 1998-08-14 Encapsulation of living tissue cells in a microsphere

Country Status (6)

Country Link
US (1) US5895757A (en)
EP (1) EP1007634A1 (en)
JP (1) JP2001514880A (en)
CN (1) CN1292816A (en)
AU (1) AU8784398A (en)
WO (1) WO1999009142A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2785292A1 (en) * 1998-10-30 2000-05-05 Rhodia Chimie Sa CAPSULES WITH POROUS MINERAL SHELL IN WHICH ARE IMMOBILIZED IN A LIQUID BIOLOGICAL MEDIUM, ONE OR MORE BIOLOGICAL MATERIALS, THEIR PREPARATION PROCESS AND USES

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1104287T1 (en) * 1998-08-13 2001-12-20 Sol Gel Technologies Ltd METHOD FOR PRODUCING OXIDE MICROCAPSULES LOADED WITH FUNCTIONALIZED MOLECULES AND THE PRODUCTS OBTAINED FROM THEM
US6818594B1 (en) 1999-11-12 2004-11-16 M-I L.L.C. Method for the triggered release of polymer-degrading agents for oil field use
NZ531316A (en) 1999-11-12 2005-08-26 Mi Llc Method and composition for the triggered release of polymer-degrading agents for oil field use
US7758888B2 (en) 2000-04-21 2010-07-20 Sol-Gel Technologies Ltd. Composition exhibiting enhanced formulation stability and delivery of topical active ingredients
CN100453162C (en) * 2003-07-31 2009-01-21 索尔-格尔科技有限公司 Microcapsules loaded with active ingredients and a method for their preparation
AU2004229070A1 (en) * 2003-11-13 2005-06-02 Dale C. Gyure Novel bioreactor
CN1319525C (en) * 2004-09-16 2007-06-06 北京圣医耀科技发展有限责任公司 Taxinol-sodium alginate micro ball vascular embolism agent and its preparation
AU2006274541B2 (en) * 2005-08-02 2012-12-13 Sol-Gel Technologies Ltd. Metal oxide coating of water insoluble ingredients
CN101594854B (en) * 2006-12-28 2012-02-08 陶氏康宁公司 Polynuclear microcapsules
BRPI0808160A2 (en) * 2007-02-01 2014-09-23 Sol Gel Technologies Ltd PROCESS FOR COATING A SOLID, WATER-INSOLATED PRIVATE MATERIAL WITH A METAL OXIDE, COATED PARTICULATED MATERIALS, METHODS TO TREAT A SURFACE CONDITION ON AN INDIVIDUAL, AND TO PREVENT, REDUCE, OR ELIMINATE, OR ELIMINATE, USE OF COATED PRIVATE MATERIAL
KR20090125243A (en) 2007-02-01 2009-12-04 솔-겔 테크놀로지스 리미티드 Compositions for topical application comprising a peroxide and retinoid
JP5344417B2 (en) * 2007-04-17 2013-11-20 国立大学法人群馬大学 Method for producing drug-silica inclusion body using water-oil interface
WO2011156484A2 (en) * 2010-06-08 2011-12-15 President And Fellows Of Harvard College Low-temperature synthesis of silica
US9273305B1 (en) * 2012-04-25 2016-03-01 Sandia Corporation Cell-based composite materials with programmed structures and functions
US9687465B2 (en) 2012-11-27 2017-06-27 Sol-Gel Technologies Ltd. Compositions for the treatment of rosacea
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5480582A (en) * 1993-06-30 1996-01-02 Pope; Edward J. A. Process for synthesizing amorphous silica microspheres with fluorescence behavior
US5693513A (en) * 1995-01-10 1997-12-02 Pope; Edward J. A. Encapsulation of living tissue cells in an organosilicon
US5739020A (en) * 1995-01-10 1998-04-14 Pope; Edward J. A. Encapsulation of animal and microbial cells in an inorganic gel prepared from an organosilicon

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4148689A (en) * 1976-05-14 1979-04-10 Sanraku-Ocean Co., Ltd. Immobilization of microorganisms in a hydrophilic complex gel
US4391909A (en) * 1979-03-28 1983-07-05 Damon Corporation Microcapsules containing viable tissue cells
GB8604497D0 (en) * 1986-02-24 1986-04-03 Connaught Lab Separation of islets of langerhans
US5200334A (en) * 1991-08-13 1993-04-06 The Regents Of The University Of California Sol-gel encapsulated enzyme
US5744337A (en) * 1995-12-26 1998-04-28 The United States Of America As Represented By The Secretary Of The Navy Internal gelation method for forming multilayer microspheres and product thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5480582A (en) * 1993-06-30 1996-01-02 Pope; Edward J. A. Process for synthesizing amorphous silica microspheres with fluorescence behavior
US5693513A (en) * 1995-01-10 1997-12-02 Pope; Edward J. A. Encapsulation of living tissue cells in an organosilicon
US5739020A (en) * 1995-01-10 1998-04-14 Pope; Edward J. A. Encapsulation of animal and microbial cells in an inorganic gel prepared from an organosilicon

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
POPE, E. J. A. ET AL: "Living ceramics", CERAM. TRANS. (1995), 55(SOL-GEL SCIENCE AND TECHNOLOGY), 33-49, XP002086022 *
POPE, EDWARD J. A.: "Living ceramic gels for bioartificial organs", CERAM. TRANS. (1996), 63(BIOCERAMICS: MATERIALS AND APPLICATIONS II), 17-26, XP002086021 *
POPE, EDWARD J.A. ET AL: "Bioartificial organs I: Silica gel encapsulated pancreatic islets for the treatment of diabetes mellitus", J. SOL-GEL SCI. TECHNOL. (1997), 8(1/2/3), 635-639, XP002086020 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2785292A1 (en) * 1998-10-30 2000-05-05 Rhodia Chimie Sa CAPSULES WITH POROUS MINERAL SHELL IN WHICH ARE IMMOBILIZED IN A LIQUID BIOLOGICAL MEDIUM, ONE OR MORE BIOLOGICAL MATERIALS, THEIR PREPARATION PROCESS AND USES
WO2000025761A1 (en) * 1998-10-30 2000-05-11 Rhodia Chimie Capsules with porous mineral cortex

Also Published As

Publication number Publication date
AU8784398A (en) 1999-03-08
EP1007634A1 (en) 2000-06-14
US5895757A (en) 1999-04-20
JP2001514880A (en) 2001-09-18
CN1292816A (en) 2001-04-25

Similar Documents

Publication Publication Date Title
WO1999009142A1 (en) Encapsulation of living tissue cells in a microsphere
DE69635940T2 (en) Hydrogel matrix for cell tissue storage
Pope et al. Bioartificial organs I: silica gel encapsulated pancreatic islets for the treatment of diabetes mellitus
Liao et al. Bone regeneration using adipose-derived stem cells in injectable thermo-gelling hydrogel scaffold containing platelet-rich plasma and biphasic calcium phosphate
Koo et al. Secretion of erythropoietin from microencapsulated rat kidney cells: preliminary results
Lee et al. Cell transplantation for endocrine disorders
Joseph et al. Transplantation of encapsulated bovine chromaffin cells in the sheep subarachnoid space: a preclinical study for the treatment of cancer pain
CN1146155A (en) Method for implanting encapsulated cells in a host
Klomp et al. Macroporous hydrogel membranes for a hybrid artificial pancreas. II. Biocompatibility
CN1897890A (en) Use of alginate matrices to control cell growth
CN112972760B (en) Endothelial extracellular matrix loaded 3D printing bone defect repair support and preparation method thereof
CN101903049A (en) The nephridial tissue of encapsulation
EP0727481B1 (en) Method of cultivating functioning cells from organs
CN109966557A (en) The preparation method and application of the GelMA hydrogel of local sustained release Abaloparatide or related polypeptide
CN102488925A (en) Injectable articular cartilage tissue repair material and its preparation method
WO2022142350A1 (en) Injection filling material and preparation process
RU2483756C1 (en) METHOD FOR PREPARING BIODEGRADED COMPOSITE MATRIX OF REGENERATED SILK FIBROIN Bombyx mori AND ITS USE
CN108452378B (en) 3D biological printing forming method
JP2000178180A (en) Material for forming neovascular bed for use in making capillary-rich tissue in vivo
CN100475886C (en) Method for preparing polymer material with gradient distributed surface biomacromolecule
Yang et al. Preparation and characterization of collagen microspheres for sustained release of steroidal saponins
Di-Silvio A novel application of two biomaterials for the delivery of growth hormone and its effect on osteoblasts
CN104707173A (en) Three-dimensional cell culture platform, as well as preparation method and application method thereof
US20050260178A1 (en) Delivery of an organized tissue to an organism
WO2022020446A1 (en) A hybrid bioscaffold-intravascular catheter for cellular therapies

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 98810291.9

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2000 509809

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 1998939412

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1998939412

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1998939412

Country of ref document: EP